Datametrex Acquires Medi-Call For $12.0 Million In All-Stock Transaction

Datametrex AI (TSXV: DM) continues to expand its healthcare division. The firm this morning indicated that it has closed the previously announced acquisition of Medi-Call, a private telemedicine firm based in British Columbia.

Datametrex AI's Logo

The company reportedly provides “technology driven e-health or m-health care services,” and is launching initially in BC before its planned Canada-wide launch. The operation is reportedly focused on rural and isolated communities, where access to healthcare traditionally has been problematic. Medi-Call’s services are reportedly provided on a subscription basis, with the platform to be integrated into Datametrex’s AI-tech on a post-closing basis.

Under the terms of the transaction, Medi-Call was acquired for 60.0 million units of the company at a price of $0.20 per unit, equating to a $12.0 million purchase price. Each unit contains one common share and one consideration warrant, with each warrant valid for a period of two years from the date of issuance and containing an exercise price of $0.26 per share. The firm is to be a wholly owned subsidiary of Datametrex.

The past 18 months with the pandemic has transformed our behavioural habits related to our health and well being and including seeing a doctor. With the acquisition of Medi-Call comes the addition of key medical staff and enhanced capability in the field of online medicine. With the increased capacity to screen patients, on an online basis for underlying health issues prior to undertaking an ER visit in a hospital, Medi-Call is furthering its commitment to patients that require immediate acute assessment or frequent visits to a doctor’s office for consultation for underlying conditions.”

Marshall Gunter, CEO

Datametrex AI last traded at $0.235 on the TSX Venture.

FULL DISCLOSURE: DataMetrex AI Limited is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DataMetrex AI Limited on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply